DARMSTADT, Germany — (BUSINESS WIRE) — Merck, a leading science and technology company, today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients wi…
New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients
DARMSTADT, Germany — (BUSINESS WIRE) — Merck, a leading science and technology company, today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients wi…